Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5779490 | 0.82 | AHR (0.39) | SLC6A3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5777081 | 0.70 | ABCB1 (0.50) | NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL5778911 | 0.68 | MAPT (0.32) | SLC6A3MAPT | |
| SCHEMBL5778551 | 0.67 | MAPT (0.37) | SLC6A3NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL5777255 | 0.66 | MAPT (0.36) | NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL6177757 | 0.66 | IDO1 (0.40) | — | |
| SCHEMBL3865314 | 0.65 | ALDH1A1 (0.38) | NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL8870424 | 0.64 | — | — | |
| SCHEMBL4848561 | 0.62 | KDR (0.39) | NPC1RAB9A | |
| SCHEMBL3823300 | 0.62 | ELANE (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276433-A1 | Hydrazone derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-12-07 | — | — | US | disclosed |
| EP-1612204-A1 | HYDRAZONE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276433-A1 | Hydrazone derivative | APP, PRNP, HTT | SLC6A3 2721/4885NPC1 952/4885RAB9A 3127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.